Chlamydia Infection Diagnostics And Therapeutics Market size was valued at USD 2.6 billion in 2021 and is expected to reach USD 3.9 billion by 2028, at a CAGR of 6.1% during the forecast period 2022-2028. Chlamydia is a sexually transmitted disease (STD) caused by the bacteria Chlamydia trachomatis, and it can be transmitted to a baby at birth. chlamydia infection diagnostics and therapeutics market usually doesn’t have any symptoms but often infected may have symptoms such as genital pain and genital discharge both in men and women. Furthermore, chlamydia infection can cause health complications such as preventing women from getting pregnant or even endangering their pregnancies. Some people may experience pain in the lower abdomen, pelvis, testicle or vagina and may also have eye discharge or spotting. Treatment may include antibiotics, and anti-inflammatory agents and a hospital stay may be required. The global chlamydia infection diagnostics and therapeutics market is growing at significant rates owing to the prevalence rate of sexually transmitted diseases. According to World Health Organization (WHO), worldwide, more than one million sexually transmitted infections are acquired every day. Each year, an estimate of 131 million new cases of chlamydia infection are reported. Companies are focusing on the development of new ways to detect chlamydia infection in the initial stages. For instance, in December 2016, F. Hoffmann-La Roche AG launched Cobas 6800/8800 systems for the detection of Chlamydia trachomatis and Neisseria Gonorrhoea (NG) DNA.
In October 2016, Becton Dickinson and Company (BD) received U.S. FDA approval for BD Max Vaginal Panel, for detection of most common causes of vaginal infections including chlamydia trichomoniasis.